GLYDO

Post-LOE

lidocaine hydrochloride

Sagent Pharmaceuticals

ANDATOPICALJELLY

Approved

Apr 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Intelligence

6/8 — Comprehensive

GLYDO (lidocaine hydrochloride) by Sagent Pharmaceuticals is impulses, thereby effecting local anesthetic action. Approved for control of pain in procedures involving the male, female urethra () for topical treatment of painful urethritis (), nasal endotracheal intubation (). First approved in 2014.

See 4 jobs working on GLYDO →

Mechanism of Action

impulses, thereby effecting local anesthetic action.

Indications (3)

control of pain in procedures involving the male female urethra () for topical treatment of painful urethritis ()

Worked on GLYDO at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

GLYDO

Mechanism of Action

Indications (3)

Clinical Trials (1)

Why This Matters for Your Career